ERBB2 and breast cancer: In a phase III clinical trial, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, neratinib has been tested for its efficacy and safety after trastuzumab-based adjuvant therapy in a cohort of 2840 patients with early stage HER2+ BC [65].